DXCM logo

DexCom (DXCM) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

14 April 2005

Description:

DexCom, Inc. is a company specializing in the development and production of medical equipment with headquarters in San Diego, California. It is mainly involved in the development and implementation of devices for continuous glucose monitoring (CGMS) in patients with diabetes. It was founded in 1999. The company's product portfolio includes DexCom G6 and DexCom G6 Pro (the first integrated type of CGMS approved by the FDA for use with other compatible medical devices and electronic interfaces), DexCom G5 Mobile (which allows the company's transmitter to run Software 505 algorithm and directly connect to the patient's compatible mobile device, including iPhone, iPod touch, iPad, and some Android devices), DexCom G4 PLATINUM, and DexCom Share.

Events Calendar

Earnings

Next earnings date:

Feb 07, 2025

Recent quarterly earnings:

Oct 24, 2024

Recent annual earnings:

Feb 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

June 13, 2022

Analyst ratings

Recent major analysts updates

11 Dec '24 Wells Fargo
Overweight
11 Dec '24 Citigroup
Buy
09 Dec '24 Canaccord Genuity
Buy
25 Oct '24 Wells Fargo
Overweight
25 Oct '24 Raymond James
Strong Buy
25 Oct '24 RBC Capital
Outperform
25 Oct '24 Oppenheimer
Outperform
25 Oct '24 Leerink Partners
Outperform
25 Oct '24 JP Morgan
Neutral
25 Oct '24 Bernstein
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Zacks Investment Ideas feature highlights: DexCom and Albemarle
Zacks Investment Ideas feature highlights: DexCom and Albemarle
Zacks Investment Ideas feature highlights: DexCom and Albemarle
DXCM
Zacks23 December 2024

DexCom and Albemarle are included in the Zacks Investment Ideas article.

Abbott and DexCom settle glucose monitor patent disputes
Abbott and DexCom settle glucose monitor patent disputes
Abbott and DexCom settle glucose monitor patent disputes
DXCM
reuters.com23 December 2024

On Monday, Abbott Laboratories announced that it has come to an agreement with DexCom to resolve all patent conflicts concerning continuous glucose monitoring devices.

DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
DXCM
zacks.com23 December 2024

DexCom (DXCM) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. Recent changes in earnings estimates may lead to an additional increase in the stock price soon.

1 Reason to Sell DexCom Stock, and 1 Reason to Buy
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
DXCM
fool.com21 December 2024

The shares of DexCom, a company that makes medical devices, have fallen by 37% this year. Investors were let down by the company's second-quarter results, which caused a significant drop in its stock price overnight.

Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
DXCM
businesswire.com19 December 2024

NEW YORK--(BUSINESS WIRE)--EDO, a company focused on TV outcomes, has published its Q3 2024 report on Diabetes Convergent TV Outcomes. This report offers important insights into how linear and streaming TV ads perform in the diabetes sector, highlighting key factors that influence consumer engagement. It shows that GLP-1 drugs are changing diabetes management and that advertisers are putting more money into convergent TV to reach this expanding audience.

DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
DXCM
zacks.com18 December 2024

Dexcom has introduced the first Generative AI platform for glucose biosensing. This new technology aims to improve the way glucose levels are monitored.

Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
DXCM
cnbc.com17 December 2024

On Tuesday, Dexcom revealed its first generative AI feature for the Stelo biosensor, which provides users with a customized weekly report on their glucose levels. The company has been developing a generative AI platform using technology from Google Cloud.

Dexcom Launches the First Generative AI Platform in Glucose Biosensing
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
DXCM
businesswire.com17 December 2024

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a leader in glucose monitoring, has introduced a unique Generative AI (GenAI) platform, becoming the first continuous glucose monitor (CGM) maker to use GenAI in its technology. This new platform will examine personal health data to show how lifestyle choices affect glucose levels and offer practical advice to enhance metabolic health.

DexCom: Brighter 2025 From Stelo Ramp
DexCom: Brighter 2025 From Stelo Ramp
DexCom: Brighter 2025 From Stelo Ramp
DXCM
seekingalpha.com10 December 2024

In 2024, DexCom is dealing with challenges from competition and some mistakes, but the future for continuous glucose monitors looks promising. In the third quarter, their revenue increased by just 2% year-on-year to $994.2 million, affected by both short-term and long-term difficulties that impacted growth and profit margins. They launched a new over-the-counter product called Stelo CGM in August, which aims to attract non-insulin users, and they expect significant growth from it in 2025.

3 Reasons to Buy DexCom Stock Like There's No Tomorrow
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
DXCM
fool.com02 December 2024

DexCom, a specialist in medical devices, is currently facing challenges. Its stock has dropped significantly this year because of disappointing financial performance, and some of the difficulties it has faced are certainly worrying.

FAQ

  • What is the primary business of DexCom?
  • What is the ticker symbol for DexCom?
  • Does DexCom pay dividends?
  • What sector is DexCom in?
  • What industry is DexCom in?
  • What country is DexCom based in?
  • When did DexCom go public?
  • Is DexCom in the S&P 500?
  • Is DexCom in the NASDAQ 100?
  • Is DexCom in the Dow Jones?
  • When was DexCom's last earnings report?
  • When does DexCom report earnings?
  • Should I buy DexCom stock now?

What is the primary business of DexCom?

DexCom, Inc. is a company specializing in the development and production of medical equipment with headquarters in San Diego, California. It is mainly involved in the development and implementation of devices for continuous glucose monitoring (CGMS) in patients with diabetes. It was founded in 1999. The company's product portfolio includes DexCom G6 and DexCom G6 Pro (the first integrated type of CGMS approved by the FDA for use with other compatible medical devices and electronic interfaces), DexCom G5 Mobile (which allows the company's transmitter to run Software 505 algorithm and directly connect to the patient's compatible mobile device, including iPhone, iPod touch, iPad, and some Android devices), DexCom G4 PLATINUM, and DexCom Share.

What is the ticker symbol for DexCom?

The ticker symbol for DexCom is NASDAQ:DXCM

Does DexCom pay dividends?

No, DexCom does not pay dividends

What sector is DexCom in?

DexCom is in the Healthcare sector

What industry is DexCom in?

DexCom is in the Medical Devices industry

What country is DexCom based in?

DexCom is headquartered in United States

When did DexCom go public?

DexCom's initial public offering (IPO) was on 14 April 2005

Is DexCom in the S&P 500?

Yes, DexCom is included in the S&P 500 index

Is DexCom in the NASDAQ 100?

Yes, DexCom is included in the NASDAQ 100 index

Is DexCom in the Dow Jones?

No, DexCom is not included in the Dow Jones index

When was DexCom's last earnings report?

DexCom's most recent earnings report was on 24 October 2024

When does DexCom report earnings?

The next expected earnings date for DexCom is 7 February 2025

Should I buy DexCom stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions